The Vaccines are Coming!
DISCLAIMER

The information presented today is based on CDC’s recent guidance and MAY change.

December 08, 2020
Discussion Topics

• Welcome and Opening Remarks
• COVID-19 Vaccine Updates
• Expert Vaccine Allocation Panel
• COVID-19 Texas Vaccine Allocation & Shipment
• COVID-19 Vaccine Storage, Handling & Administration
• COVID-19 Vaccine Safety Monitoring & Reporting
• Q&A
Welcome & Opening Remarks

Imelda Garcia, MPH
Associate Commissioner, Laboratory & Infectious Disease Services Division
COVID-19 Vaccine Allocations - Week 1

FOR PLANNING PURPOSES ONLY

COVID-19 Vaccine Storage Type
- Ultra-cold Capacity (n=51)
- Dry Ice Needed (n=50)
- Public Health Region

As of December 7, 2020
COVID-19 Vaccine Updates

Saroj Rai, PhD, MPH
## COVID-19 Vaccine Updates

<table>
<thead>
<tr>
<th>Phase III Vaccine Candidates</th>
<th>Technology Platform</th>
<th>Storage &amp; Handling</th>
<th>Dose (Intramuscular Injection)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Pfizer</td>
<td>m-RNA</td>
<td>Ultra-low frozen: 6mos Refrigerated: 5 days</td>
<td>2 (0, 21 days)</td>
</tr>
<tr>
<td>Moderna</td>
<td>m-RNA</td>
<td>Frozen: 6mos Refrigerated: 30 days</td>
<td>2 (0, 28 days)</td>
</tr>
<tr>
<td>AstraZeneca + University of Oxford</td>
<td>Viral Vector (Non-Replicating)</td>
<td>Refrigerated: 6mos</td>
<td>2 (0, 28 days)</td>
</tr>
<tr>
<td>Janssen</td>
<td>Viral Vector (Non-Replicating)</td>
<td>Refrigerated: 6mos</td>
<td>1</td>
</tr>
<tr>
<td>Phase III Vaccine Candidates</td>
<td>Technology Platform</td>
<td>Study Design</td>
<td>Efficacy &amp; Safety</td>
</tr>
<tr>
<td>-----------------------------</td>
<td>---------------------</td>
<td>--------------</td>
<td>------------------</td>
</tr>
<tr>
<td>Pfizer</td>
<td>m-RNA</td>
<td>• N=44,000</td>
<td>Interim Analysis</td>
</tr>
<tr>
<td></td>
<td></td>
<td>• ≥ 12 yrs</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>• Randomization (1:1)</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>• Placebo vs. Vaccine</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>• (Saline vs. 30 µg)</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>• 2 doses (0, 21 days)</td>
<td></td>
</tr>
<tr>
<td>Moderna</td>
<td>m-RNA</td>
<td>• N=30,000</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>• ≥ 18 yrs</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>• Randomization (1:1)</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>• Placebo vs. Vaccine</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>• (Saline vs. 100 µg)</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>• 2 doses (0, 28 days)</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Viral Vector (Non-Replicating)</td>
<td>• UK Study</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>• N=12,390</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>• ≥ 18 yrs</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>• 1 Dose vs. 2 Doses vs. MenACWY</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>• Brazil Study</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>• N=10,300</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>• ≥ 18 yrs</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>• 2 does vaccine vs. MenACWY/Saline</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Viral Vector (Non-Replicating)</td>
<td>• Janssen</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>• N=60,000</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>• ≥ 18 yrs</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>• Randomization (1:1)</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>• Placebo vs. Vaccine</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>• (Saline vs. 5x10^{10} vp)</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>• 1 doses</td>
<td></td>
</tr>
</tbody>
</table>
Path to Vaccination
PFIZER

Dec. 10 → Dec. 11-14 → Dec. 11-14 → Dec. 14-18

Begin Vaccination

VRBPAC
Open Session Meeting

FDA
Reviews all the Data

EUA

CDC ACIP Calls an Immediate Meeting

Recommendations

Dec. 10
Dec. 11-14
Dec. 11-14
Dec. 14-18

BLA (Biologics Licensure Application)
EUA (Emergency Use Authorization)
EA (Expanded Access)
VRBPAC Open Session Meeting

FDA Reviews all the Data

EUA

CDC ACIP Calls an Immediate Meeting

Recommendations

MODERNA

Dec. 17

Dec. 18-21

Dec. 18-21

Dec. 21-23

Vaccination

BLA (Biologics Licensure Application)
EUA (Emergency Use Authorization)
EA (Expanded Access)
Expert Vaccine Allocation Panel (EVAP)

Imelda Garcia, MPH
Associate Commissioner, Laboratory & Infectious Disease Services Division
COVID-19 Expert Vaccination Allocation Panel (EVAP)

• Texas has convened a team of appointed external and internal subject-matter experts (SME) into the COVID-19 Expert Vaccine Allocation Panel (EVAP) to develop vaccine allocation strategies as recommendations to the Texas Commissioner of Health.

• The panel will develop and apply guiding principles in their recommendations.

• The recommendations from the EVAP will be sent to the Texas Commissioner of Health for final approval.

• EVAP voting members
Texas Guiding Principles

• **Protecting health care workers** who fill a critical role in caring for and preserving the lives of COVID-19 patients and maintaining the health care infrastructure for all who need it.
• **Protecting front-line workers** who are at greater risk of contracting COVID-19 due to the nature of their work providing critical services and preserving the economy.
• **Protecting vulnerable populations** who are at greater risk of severe disease and death if they contract COVID-19.
• **Mitigating health inequities** due to factors such as demographics, poverty, insurance status and geography.
• **Data-driven allocations** using the best available scientific evidence and epidemiology at the time, allowing for flexibility for local conditions.
• **Geographic diversity** through a balanced approach that considers access in urban and rural communities and in affected ZIP codes.
• **Transparency** through sharing allocations with the public and seeking public feedback.

COVID-19 Critical Population Update
Phase 1A Healthcare Workers Definition – First Tier

1. Hospital staff working directly with patients who are positive or at high risk for COVID-19. Includes:
   a. Physicians, nurses, respiratory therapists and other support staff (custodial staff, etc.)
   b. Additional clinical staff providing supporting laboratory, pharmacy, diagnostic and/or rehabilitation services
2. Long-term care staff working directly with vulnerable residents. Includes:
   a. Direct care providers at nursing homes, assisted living facilities, and state supported living centers
   b. Physicians, nurses, personal care assistants, custodial, food service staff
3. EMS providers who engage in 9-1-1 emergency services like pre-hospital care and transport
4. Home health care workers, including hospice care, who directly interface with vulnerable and high-risk patients
5. Residents of long-term care facilities
COVID-19 Critical Population Update
Phase 1A Healthcare Workers Definition – Second Tier

1. Staff in outpatient care offices who interact with symptomatic patients. Includes:
   a. Physicians, nurses, respiratory therapists and other support staff (custodial staff, etc.).
   b. Clinical staff providing diagnostic, laboratory, and/or rehabilitation services
   c. Non 9-1-1 transportation for routine care
2. Direct care staff in freestanding emergency medical care facilities and urgent care clinics.
3. Community pharmacy staff who may provide direct services to clients, including vaccination or testing for individuals who may have COVID.
4. Public health and emergency response staff directly involved in administration of COVID testing and vaccinations.
5. Last responders who provide mortuary or death services to decedents with COVID-19. Includes:
   • Embalmers and funeral home workers who have direct contact with decedents
   • Medical examiners and other medical certifiers who have direct contact with decedents.
6. School nurses who provide health care to students and teachers.
COVID-19 Texas Vaccine Allocation Process

Joshua Hutchison, Vaccine Data and Finance Manager
Vaccine Allocation & Ordering System (VAOS)
Overview
As a COVID-19 Vaccine Provider, you will use the Vaccine Allocation & Ordering System (VAOS) and Vaccine Management Dashboard to perform tasks related to COVID-19 vaccine management.

In VAOS, you will be able to acknowledge vaccine allocations, confirm received shipments, view distribution information, and report waste.

The Vaccine Management Dashboard is accessed through VAOS and allows you to monitor your vaccine allocations, distribution supply, and administration metrics.
# Understanding your Provider Actions in VAOS

As a Provider, you have **four primary functions in VAOS:**

<p>| | | | |</p>
<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>1</strong></td>
<td><strong>2</strong></td>
<td><strong>3</strong></td>
<td><strong>4</strong></td>
</tr>
</tbody>
</table>
| ACCESSING DASHBOARDS  
Useful for seeing your allocations, distribution supply, and administration metrics | ACKNOWLEDGING ALLOCATIONS  
Required for your allocated vaccine doses to be submitted into the CDC ordering system | CONFIRMING SHIPMENTS  
Required once you receive your vaccine doses | REPORTING WASTE  
Required to track how many doses are unused/wasted |
Key Vaccine Management Actions for Providers

Use VAOS to accept, reduce, or reject your allocation

Receive allocation email from noreply@salesforce.com

Receive your vaccine shipment & confirm receipt in VAOS

Receive a shipment confirmation email from noreply@salesforce.com

Report administration of vaccine and adverse event in ImmTrac2

Report any dosage waste in VAOS
Pfizer Vaccine Candidate Shipment
Direct Shipments* to Vaccination Center by Transport Courier

Pfizer has designed a distribution model which is built on a flexible just in time system to ship the vaccine from manufacturing site and/or storage facility directly to the points of vaccination.

Temperature & Location Tracking During Transportation

- Each thermal shipper has reusable GPS enabled temperature monitoring device which will be enabled when the shipper is packed.
- All shipments will be tracked via the onboard GPS monitoring device to ensure end-to-end distribution within required temperatures.
- Shipments will be executed under the management of Pfizer Quality processes and controls to ensure that upon ownership transfer, product has arrived under acceptable conditions.
- Temperature records of the shipments can be shared with upon request.

*COVID Vaccine supply chain model is a drop ship direct from Pfizer manufacturing sites to the designated locations by the government.

Product ownership transfer at port of entry for governmental customer importation and in-market distribution

Current as of December 2020, Operation Warp Speed has requested that prior to the potential FDA authorization of the Pfizer-BioNTech Covid-19 Vaccine, Pfizer send select training materials containing information for properly storing, preparing and administering the vaccine to anticipated vaccination sites. Although there is no guarantee that the vaccine will be authorized by FDA, given the urgency of the pandemic, providing these materials in advance will enhance sites’ preparation. Materials, specifications and assumptions are subject to change. For the most up-to-date materials upon authorization, please visit www.covidevaccine.com. Pfizer will not begin shipment of the vaccine unless and until FDA has
Vaccine Shipment – Provider Emails

Once the EUA has been issued and the vaccine is ready for distribution, you will receive shipment information and tracking numbers from the vendors. Please ensure that you are able to receive e-mails from the following addresses:

<table>
<thead>
<tr>
<th>Email Address</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td><a href="mailto:cvgovernment@pfizer.com">cvgovernment@pfizer.com</a></td>
<td>Pfizer Customer Service</td>
</tr>
<tr>
<td><a href="mailto:Pfizer.logistics@controlant.com">Pfizer.logistics@controlant.com</a></td>
<td>For communication from Controlant, including:</td>
</tr>
<tr>
<td></td>
<td>• Notice at time of vaccine shipment with tracking information</td>
</tr>
<tr>
<td></td>
<td>• Exceptions for either shipment delay or cancellation</td>
</tr>
<tr>
<td></td>
<td>• Delivery Quality Report</td>
</tr>
<tr>
<td><a href="mailto:SNSSupport@McKesson.com">SNSSupport@McKesson.com</a></td>
<td>For communication from McKesson about ancillary kits</td>
</tr>
</tbody>
</table>

Please note, for the first shipment, you will receive ancillary supplies between Dec 9-11, prior to the arrival of the vaccine.
COVID-19 Texas Vaccine Allocation Summary

- Weekly allocation
- No need to hold back vaccine for the 2\textsuperscript{nd} dose
- Please report doses administered into ImmTrac2 within 24 hours
- Please ensure all contact information is correct in the provider portal
- Ensure able to receive emails from the specific email addresses
Pfizer Vaccine Candidate
Storage, Handling and Administration

Saroj Rai, PhD, MPH
Overview of Shipping, Storage & Handling

1. Thermal Shipper Arrival
The thermal shipper that the vaccine arrives in can be used as temporary storage, so long as dry ice is replenished upon receipt and every 5 days (up to 30 days).

The thermal shipper maintains a temperature range of -90°C to -60°C (-130°F to -76°F). Storage within this temperature range is not considered an excursion from the recommended storage condition.

2. Storage & Handling
Storage options for vials/trays include:

1. **Ultra Low Temperature Freezer** at -80° and -60°C (-112 to -76°F) for up to 6 months
2. **Thermal Shipper** at -90°C to -60°C (-130°F to -76°F) for up to 30 days from delivery, if replenished with dry ice upon receipt and every 5 days
3. **Refrigerator** at 2 to 8°C (35.6° to 46.4°F) for up to 120 hours (5 days)

Vials are glass and should be handled with care. Visual inspection prior to use should be carried out.

Vials should be protected from light and kept in the original packaging.

Vials should always remain upright in trays during storage.

3. Returning Thermal Shipper
The thermal shipping container may be used as temporary storage for up to 30 days from delivery, including temperature data logger.

Current as of December 2020, Operation Warp Speed has requested that prior to the potential FDA authorization of the Pfizer-BioNTech Covid-19 Vaccine, Pfizer send select training materials containing information for properly storing, preparing and administering the vaccine to anticipated vaccination sites. Although there is no guarantee that the vaccine will be authorized by FDA, given the urgency of the pandemic, providing these materials in advance will enhance sites’ preparation. Materials, specifications and assumptions are subject to change. For the most up-to-date materials upon authorization, please visit www.cdcvaccine.gov. Pfizer will not begin shipment of the vaccine unless and until FDA has...
## Ultra Low Temperature Thermal Shipper – Overview of Pack Out

### Softbox Medium ULT Weights and Dimension

<table>
<thead>
<tr>
<th>ITEM</th>
<th>DESCRIPTION</th>
<th>Weight</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>VIP LID</td>
<td>8.5 kgs</td>
</tr>
<tr>
<td>2</td>
<td>DRY ICE POD</td>
<td>23 kgs</td>
</tr>
<tr>
<td>3</td>
<td>PAYLOAD SLEEVE (Takes 1 to 5 vial trays)</td>
<td>31.5 kgs</td>
</tr>
<tr>
<td>4</td>
<td>MEDIUM ULT THERMAL SHIPPER</td>
<td>32.6 kgs</td>
</tr>
</tbody>
</table>

- **Tare Weight w/ Dry Ice**: 31.5 kgs
- **Total Weight w/ 1 Vial Tray**: 32.6 kgs
- **Total Weight w/ 5 Vial Trays**: 36.7 kgs

**Weight of Vial Tray**: 1.038 kgs

**Available Payload Space**: 9.65" x 9.65" x 9.49"

**External Dimension**: 15.75" x 15.75" x 22.04"
**Ultra-Low Temperature Freezer (ULTF)**

**Temperature**
- Store as frozen liquid at -80°C to -60 °C (-112°F to -76°F) for long term storage up to 6 months.
- Different size of ULT freezers are may be available for purchase by points of vaccination.
- A small size (under or over the countertop ULT Freezers can store as much as 30K doses).

**Product Transfer from Thermal Shipper to ULTF**

1. Remove Dry Ice Pod from shipper.
2. Remove the Payload Box from the thermal shipper by carefully pulling directly upwards with the handles.
3. Immediately store vial trays in an ultra-low temperature (ULT) freezer. Do not open the vial trays until you are ready to remove vials for thawing or use.

Monitor freezer temperatures.

*Product temperature must always be monitored to ensure adherence to temperature requirements for different storage conditions are being met in alignment with site Standard Operating Procedures.*

Please note that it is possible that the final preparation and logistical requirements may change in light of forthcoming data on dosing, stability, manufacturing and shipping requirements, but this deck reflects the Company's current understanding based on the totality of available data currently. (Current as of September 8, 2021)
### Product Packaging Overview

#### Vials
- 2 mL Type 1 glass preservative-free

- 2 mL type 1 glass preservative-free multi-dose vial (MDV)
- MDV has 0.45 mL frozen liquid drug product
- 5 doses per vial after dilution

#### Trays
- Single tray holds 195 vials
- 975 doses per tray
- A smaller tray, containing 25 vials (125 doses) is in development with estimated availability in early 2021

#### Thermal Shipper
- Minimum 1 tray (975 doses) or up to 5 trays (4875 doses) stacked in a payload area of the shipper
- Payload carton submerged in dry ice pellets
- Thermal shipper keeps ULT -90°C to -60°C (-130°F to -76°F) up to 10 days if stored at 15°C to 25°C (5°F to 77°F) temperatures without opening
- Thermal shippers are reusable and designed to be a temporary storage containers by replenishing dry ice.

---

Current as of December 2020, Operation Warp Speed has requested that prior to the potential FDA authorization of the Pfizer-BioNTech Covid-19 Vaccine, Pfizer send select training materials containing information for properly storing, preparing and administering the vaccine to anticipated vaccination sites. Although there is no guarantee that the vaccine will be authorized by FDA, given the urgency of the pandemic, providing these materials in advance will enhance sites’ preparation. Materials, specifications and assumptions are subject to change. For the most up-to-date materials upon authorization, please visit www.covidvaccine.com. Pfizer will not begin shipment of the vaccine unless and until FDA has authorized or licensed the vaccine.
**Key Timing Considerations**

**TRAYS**

- **3 MINS**
  
  Open-lid vial trays, or vials trays containing less than 195 vials removed from frozen storage (< -60°C) may be at room temperature (< 25°C) for up to 3 minutes for transfer between ultra low temperature environments or to remove vials for thawing or use.

- **5 MINS**
  
  Closed-lid vial trays containing 195 vials removed from frozen storage (< -60°C) may be at room temperature (< 25°C) for up to 5 minutes for transfer between ultra low temperature environments.

- **2 HRS**
  
  After vial trays are returned to frozen storage following room temperature exposure, they must remain in frozen storage for at least 2 hours before they can be removed again.

**VIALS**

- Once an individual vial is removed from a vial tray at room temperature, it should **not be returned to frozen storage** and should be thawed for use.
# Cold Storage Comparison

<table>
<thead>
<tr>
<th>Cold Storage Limitations</th>
<th>ULTF (up to 6 months)</th>
<th>Thermal (up to 30 Days)</th>
<th>Fridge (up to 5 Days)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Availability of Full-time Immunizers</td>
<td>No Restriction</td>
<td>Minimum 2 Immunizers</td>
<td>Minimum 4 Immunizers</td>
</tr>
<tr>
<td>Anticipated Patient Flow</td>
<td>Minimum 960 patients in 6 months</td>
<td>Minimum 960 patients in 30 days</td>
<td>Minimum 960 patients in 5 days</td>
</tr>
<tr>
<td>Allows for Variability in Patient Flow (e.g. walk-ins)</td>
<td>Yes</td>
<td>No</td>
<td>No</td>
</tr>
<tr>
<td>Requires Dry Ice Ordering/ Handling</td>
<td>No</td>
<td>Yes</td>
<td>No</td>
</tr>
</tbody>
</table>
Refrigerator Usage

Product Refrigeration

Product can be stored at 2 to 8 °C (35.6° to 46.4°F) refrigerator up to 120 hours (5 days).

Product Thawing

Based on current stability studies, a tray of 25 vials or 195 vials may take up to 2 or 3 hours to thaw in the refrigerator, respectively, whereas a fewer number of vials will thaw in less time.

Either: Transfer the frozen vials immediately to a refrigerator at 2 to 8 °C (35.6° to 46.4°F).

Or: Vials needed for immediate use can be thawed at room temperature (30 minutes); room temperature hold time is no more than 2 hours.

Vials thawed at room temperature form condensation on the outside of the vial, so thawing in a secondary container is recommended.

Vials may be stored in the refrigerator prior to dilution for up to 5 days (120 hours).

Vials may be held at room temperature for no more than 2 hours prior to dilution.
Re-icing Thermal Shipper

Handling instructions
- Re-ice at a minimum of every 5 days (based on normal use). No restriction to number of re-icing.
- If box is left open for longer than 3 minutes, recommendation is to re-ice more frequently, as needed.
- If re-icing occurs and a holiday or weekend, plan ahead to re-ice the thermal shipping container.
- Thermal shipping container may be used as temporary storage for up to 30 days from delivery.
- Sites are required to maintain temperature monitoring.

Thermal Shipper opening:
- twice daily, max 3 minutes each

Shipper arrives with 80% energy
Upon receipt and after opening, the box should be replenished/inspected with dry ice within 24 hours
Re-ice shipper
Re-ice shipper
Re-ice shipper
Re-ice shipper
Re-ice shipper
Return shipper

SHIPPER ENERGY LEVEL
Vaccine Preparation and Administration

Removing the Vials to Thaw

From storage, remove 1 vial for every 5 recipients according to planned vaccinations schedule.

Vials may be stored in the refrigerator for 5 days (120 hours).

Dilute the Vaccine

Obtain 0.9% Sodium Chloride Injection, USP for use as a diluent.
Do not use any alternate diluents.

Dilute the thawed vial by adding 1.8 mL of 0.9% Sodium Chloride Injection into the vial.

Preparing the Dose

Draw up 0.3 mL of the diluted dosing solution into a new sterile dosing syringe with a needle appropriate for intramuscular injection.

For each additional dose, use a new sterile syringe and needle and ensure the vial stopper is cleansed with antiseptic before each withdrawal.

Vaccine Administration

Pfizer BioNTech COVID-19 Vaccine
30 mcg/0.3 mL

A single 30 mcg/0.3 mL dose followed by a second dose 21 days later.

*21 DAYS*
Vaccine Preparation Instruction

Supplies Required to Prepare:

- 1 Vial Pfizer BioNTech COVID-19 Vaccine
- 1 Vial 0.9% Sodium Chloride Injection (at least 2 mL)
- 1 diluent syringe/needle (3 mL or 5mL syringe/21 G needle recommended)
- 5 dosing syringes/needles (1 mL syringe/ IM injection needle)
- Other ancillary materials such as alcohol swabs, gloves, PPE
COVID-19 Vaccine Safety Monitoring
# COVID-19 Vaccine Safety Monitoring

<table>
<thead>
<tr>
<th>Monitoring Plan</th>
<th>Type</th>
<th>Lead Federal Agency</th>
<th>Collaborating Agencies and Partners</th>
</tr>
</thead>
<tbody>
<tr>
<td>Vaccine Adverse Event Reporting System (VAERS)</td>
<td>Passive</td>
<td>CDC</td>
<td>FDA</td>
</tr>
<tr>
<td>Biologics Effectiveness and Safety (BEST) System</td>
<td>Active</td>
<td>FDA</td>
<td>Several Health Plans, Academia, IBM Watson</td>
</tr>
<tr>
<td>FDA-Center for Medicare &amp; Medicaid Services (CMS) Partnership</td>
<td>Active</td>
<td>FDA</td>
<td>CMS</td>
</tr>
<tr>
<td>FDA and other Government Entities Partnership</td>
<td>Active / Passive</td>
<td>FDA</td>
<td>CDC, CMS, VA, NIH, DOD &amp; IHS</td>
</tr>
<tr>
<td>Vaccine Effectiveness Surveillance Plans</td>
<td>Passive</td>
<td>FDA</td>
<td>CDC</td>
</tr>
<tr>
<td>Vaccine Safety Datalink (VSD)</td>
<td>Passive</td>
<td>CDC</td>
<td>9 Health Plans</td>
</tr>
<tr>
<td>Clinical Immunization Safety Assessment (CISA) Project</td>
<td>Active</td>
<td>CDC</td>
<td>7 Medical Research Centers</td>
</tr>
<tr>
<td>V-safe</td>
<td>Active</td>
<td>CDC</td>
<td>FDA</td>
</tr>
</tbody>
</table>
VAERS is the nation’s frontline system for monitoring vaccine safety.
**v-safe | after vaccination health checker**

**V-safe** is a smartphone-based tool that uses text messaging and web surveys to provide **personalized health check-ins** after someone receives a COVID-19 vaccination.

Vaccine recipients can quickly tell the CDC if they have any side effects. The CDC may follow up with them by phone to get more information.

**V-safe** will also remind them to get their second COVID-19 vaccine dose, if needed.
How long do v-safe check-ins last?

• During the first week after you get your vaccine, **v-safe** will send you a text message each day to ask how you are doing.

• Then you will get check-in messages once a week for up to 5 weeks.

• The questions **v-safe** asks should take less than 5 minutes to answer.

• If you need a second dose of vaccine, **v-safe** will provide a new 6-week check-in process so you can share your second-dose vaccine experience as well.

• You’ll also receive check-ins 3, 6, and 12 months after your final dose of vaccine.
v-safe | your role as a provider

• Give patients a **v-safe** information sheet at the time of vaccination

• Encourage them to enroll and fill out the surveys when prompted

https://vsafe.cdc.gov/
Resources

• COVID-19 Vaccine Provider Registration Information: www.dhs.texas.gov/coronavirus/immunize/provider-information.aspx

• FAQ for Providers https://www.dhs.texas.gov/immunize/covid19/COVIDproviderfaq.pdf

• DSHS COVID-19 Vaccine Provider hotline:

• (877) 835-7750, 8 a.m. to 5 p.m., Monday through Friday or Email: COVID19VacEnroll@dshs.texas.gov

• Website to enroll as a COVID-19 Vaccine Provider: EnrollTexasIZ.dshs.texas.gov
The information presented today is based on CDC’s recent guidance and MAY change.

December 08, 2020